Core Insights - The gene synthesis industry is a subset of DNA synthesis, focusing on the artificial creation of long double-stranded DNA with specific sequences, which is crucial for synthetic biology [1][3] - The Chinese gene synthesis market is projected to reach approximately 14.3 billion yuan in 2023, reflecting significant growth driven by government support and technological advancements [1][5] - BGI Genomics, a leading company in the Chinese gene synthesis sector, has established a comprehensive marketing network and offers a wide range of gene synthesis services [5] Industry Overview - Gene synthesis involves the chemical or enzymatic methods to artificially create genes or specific DNA sequences, with applications in basic research, biotechnology, gene therapy, and synthetic biology [3] - The industry is increasingly supported by government policies, which have integrated synthetic biology into national strategic emerging industries, fostering innovation and providing a favorable environment for growth [1][5] Market Dynamics - The integration of gene editing technologies, standardization of gene components, and advancements in microbial chassis engineering are expected to enhance the application capabilities of gene synthesis [7] - The demand for gene synthesis in the pharmaceutical sector, particularly in gene therapy and vaccine development, is anticipated to grow significantly [7] Competitive Landscape - BGI Genomics is recognized as a pioneer in the Chinese gene synthesis industry, providing various services including optimized cDNA synthesis and gene mutation services [5] - The industry analysis employs various research models such as SCP, SWOT, and PEST to evaluate market conditions, policies, competition, and technological innovations [7] Future Outlook - The report forecasts the development trends of the gene synthesis industry in China from 2025 to 2031, focusing on driving factors, constraints, and demand prospects [15][16] - The ongoing integration of artificial intelligence and machine learning is expected to significantly reduce design times and enhance the precision and efficiency of gene synthesis methods [7]

公司 完成了探路者 DNA组装核心技术 及分子牙签核心技术 平台的搭建， 已 向市场推出了定制基 因库， 将目前 长片段 基因从头合成的价格降低 至少两倍以上 ，并已开拓代谢工程、生物医药等众 多领域的工业及科研客户。 定制基因库是 公司 利用其独家拥有的探路者 DNA组装技术制备而成。 公司创始人 陈曦博士 及团 队 通过数年研究，成功证明了 DNA折叠、杂交、酶促连接等过程完全可以在仿真算法中得到足够精 细、准确的预测。在仿真算法的赋能下， 公司 可以达到高通量和低成本的基因合成 。区 别于传统 技术，探路者 DNA组装技术实现了在同一反应器中完成上千条基因的并行组装，大 幅 降低了组装 成本。但其最终交付形式与传统的基因合成相同，即经大肠杆菌菌落挑选后的、序列验证过的质粒， 确保了产品质量 。 公司 提供多种质粒载体选择，包括 pUC19、pET和pcDNA等标准载体，同时也支持客户提供的载 体。插入基因的长度范围为450 bp到10 kb，可以满足绝大部分项目的需求。 公司 创始人兼 CEO 陈曦表示： " 非常感谢本轮投资人对公司的大力支持，也感谢全体老股东对公 司的信任。 我们希望 公司 产品可以 ...